- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06918561
만성 개방 상처 치료에서 신자 FT의 효능 평가
만성 개방 상처의 치유에서 신자 FT의 효능 평가 : 무작위 대조 된 다기관 시험
This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating chronic open wounds.
연구 개요
상세 설명
This research will take place across multiple medical centers, where both researchers and participants will know which treatment is being used (open label). Patients who agree to participate and meet the study requirements during screening will be randomly assigned to one of two groups: either standard of care (SOC) alone, or SOC plus NeoThelium FT.
The study includes a crossover component for subjects in the SOC arm. At treatment visit 13 (approximately 84 days post-randomization), SOC arm subjects not having achieved complete wound closure, and still meeting the inclusion/exclusion criteria, are eligible to cross over to the IP arm (SOC plus NeoThelium FT). Crossover subjects will begin IP arm treatment with weekly NeoThelium FT applications for up to 12 treatment visits. The subject will continue follow-up per the original schedule. As this is a post-marketing study, it will gather information regarding the efficacy of treatment while also supporting insurance reimbursement decisions. All subjects will complete two-week screening phase prior to being randomized into a treatment arm. Treatment arms will consist of NeoThelium FT in conjunction with standard of care, vs. standard of care alone. The primary endpoint will be the percentage of target ulcers that achieve complete wound closure within 12 weeks. Secondary endpoints consist of wound percentage area reduction rates and pain assessment.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Angelina Ferguson, DNP
- 전화번호: (985) 629-4013
- 이메일: info@sygnola.com
연구 연락처 백업
- 이름: Sarah Moore, MBE
- 전화번호: (985) 629-4013
- 이메일: info@sygnola.com
연구 장소
-
-
Louisiana
-
Denham Springs, Louisiana, 미국, 70726
- 모병
- MedCentris of Denham Springs
-
수석 연구원:
- Monique Consoer, NP
-
연락하다:
- Tabatha Yent
- 이메일: tabatha.yent@medcentris.com
-
Hammond, Louisiana, 미국, 70403
- 모병
- MedCentris of Hammond
-
수석 연구원:
- Chris Keaton, NP
-
연락하다:
- Chelsea Smith, RN
- 이메일: Chelsea.smith@medcentris.com
-
연락하다:
- Melanie Knox, LPN
- 이메일: Melanie.knox@medcentris.com
-
Lafayette, Louisiana, 미국, 70507
- 완전한
- MedCentris of Carencro
-
Leesville, Louisiana, 미국, 71146
- 모병
- MedCentris of Leesville
-
수석 연구원:
- Stefanie Corley, FNP
-
연락하다:
- Brandi Shuff
- 이메일: Brandi.shuff@medcentris.com
-
Many, Louisiana, 미국, 71449
- 모병
- MedCentris of Many
-
수석 연구원:
- Stefanie Corley, FNP
-
연락하다:
- Brandi Shuff
- 이메일: Brandi.Shuff@medcentris.com
-
Marksville, Louisiana, 미국, 71351
- 모병
- MedCentris of Marksville
-
수석 연구원:
- Averie Rachal, FNP
-
연락하다:
- Laura Whittington
- 이메일: Laura.whittington@medcentris.com
-
Metairie, Louisiana, 미국, 70001
- 모병
- MedCentris of Metairie
-
연락하다:
- Ninya Powell
- 이메일: ninya.powell@medcentris.com
-
수석 연구원:
- Sarah Logrande, NP
-
Minden, Louisiana, 미국, 71055
- 모병
- MedCentris of Minden
-
수석 연구원:
- Taheera Forbes, NP
-
연락하다:
- Brianna Thompas
- 이메일: brianna.thompson@medcentris.com
-
Monroe, Louisiana, 미국, 71201
- 아직 모집하지 않음
- MedCentris of Monroe
-
수석 연구원:
- Libbi Trawick, NP
-
연락하다:
- Tiffany Dew
- 이메일: Tiffany.dew@medcentris.com
-
Slidell, Louisiana, 미국, 70458
- 모병
- MedCentris of Slidell
-
수석 연구원:
- Katie Schloegel, FNP
-
연락하다:
- Donyille Singletary, RN
- 전화번호: 985-602-1215
- 이메일: Donyille.singletary@medcentris.com
-
-
Mississippi
-
D'Iberville, Mississippi, 미국, 39540
- 완전한
- MedCentris of D'iberville
-
McComb, Mississippi, 미국, 39648
- 완전한
- MedCentris of McComb
-
Natchez, Mississippi, 미국, 39120
- 완전한
- MedCentris of Natchez
-
Southaven, Mississippi, 미국, 38671
- 모병
- MedCentris of Southaven
-
수석 연구원:
- Carlene McAllister, NP
-
연락하다:
- De'Nyia Woods
- 이메일: denyia.woods@medcentris.com
-
-
New York
-
Brooklyn, New York, 미국, 11234
- 모병
- Northeast Podiatry Consultant
-
연락하다:
- Thomas Hayes
- 이메일: thomas@simonfootandankle.com
-
수석 연구원:
- David Simon, DPM, FACFAS
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or Female, 18 years of age or older
- Subject has a medical diagnosis of "other" Open wound
- Subject has a chronic open wound present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC
- Subject has a chronic open wound with a historical wound measurement showing less than 25% healing within 14 days prior to screening
- Subject has a chronic open wound with screening wound measurement showing less than 25% healing within 14 days prior to randomization
- Subject has an Open wound without infection or clinically visible exposed bone
- Index wound is a minimum of 0.5cm2 and a maximum of 25cm2 at first treatment visit
- Index ulcer has a maximum depth of 1cm at screening visit 1
- The chronic open wound is treated with offloading therapy, if applicable to location, while standing, sitting, and lying down for 14 days prior to randomization
- Adequate circulation of wounds located below the knee demonstrated by an ABI of >0.7 and <1.3, or TBI of >0.6 within 30 days prior to randomization OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to randomization.
- Index ulcer is free of infection prior to randomization and during screening phase.
- Index ulcer is free of necrotic debris prior to NeoThelium FT application
- Female subjects of childbearing potential having a negative pregnancy test prior to randomization
- Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization.
- Subject is able and willing to follow the protocol requirements
- Subject had signed informed consent
- If 2 or more ulcers are present, the ulcers must be separated by at least 2 cm
Exclusion Criteria:
- Subject with a wound diagnosis of diabetic foot wound, pressure wound, venous leg wound, burn wound, or alternative diagnosis other than "open wound"
- Subject has a known life expectancy of <1 year
- Subject is unable to comply with protocol treatment
- Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing.
- Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound
- Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
- Known contraindications to tissue-engineered allograft
- Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing
- Subject is pregnant or breastfeeding
- Subject with history of immunosuppressant treatment (systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the wound surface for >2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study
- Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization
- Open wound with active infection
- Wound depth with visible exposed bone
- HBOT within 14 days prior to randomization
- Revascularization surgery on the index wound leg within 30 days of screening phase
- Index wound suspicious of neoplasm in the opinion of the principal investigator
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: No Intervention: Standard of Care
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
|
실험적: Intervention: NeoThelium FT & Standard of Care
Wound cleansing, sharps debridement, NeoThelium FT application, Dressing for moisture balance, Offloading |
NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Complete Wound Closure
기간: 1-12 weeks
|
The primary endpoint will be the percentage of target ulcers that achieve complete wound closure. |
1-12 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage Wound Area Change
기간: 1-12 weeks
|
The percentage change in wound area from TV-1 to TV-13 will be measured weekly using digital photographic planimetry and physical examination. |
1-12 weeks
|
|
Pain Assessment
기간: Day 0, Day 14, Day 35, Day 56, Day 84
|
Change in pain associated with the target ulcer will be assessed using the Numeric Pain Rating Scale at designated time points |
Day 0, Day 14, Day 35, Day 56, Day 84
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Follow-Up Closure
기간: 2 weeks
|
Number of wounds remaining closed during the 2-week follow-up |
2 weeks
|
|
Adverse Events and Serious Adverse Events
기간: Day -14 through 91 days
|
The number and nature of adverse events (AEs) and series adverse events (SAEs) occurring during the study will be tracked and reported. |
Day -14 through 91 days
|
|
Time to Closure
기간: 1-12 weeks
|
Average number of grafts and/or weeks used to achieve wound closure |
1-12 weeks
|
공동 작업자 및 조사자
협력자
수사관
- 연구 책임자: Angelina Ferguson, DNP, SygNola, LLC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- HEAL
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .